Pulmozyme for Sjogren's Associated Cough

• Status: Withdrawn
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with Sjogren's disease have destruction of the mucus secreting cells in the airway. This manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. This study is aimed at determining whether the regular use of Pulmozyme will result in decreased cough and improved quality of life.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UConn Health

Criteria

Inclusion Criteria:

• Age 18 years or above with primary Sjogren's disease (as defined by the American European Consensus Group Criteria), and complaint of chronic cough.

• Able to give consent and anticipated ability to adhere to the study procedures.

Exclusion Criteria:

• Diagnosis of COPD, emphysema, asthma, chronic bronchitis, other clinically significant lung disease that is likely to cause cough. Interstitial lung disease associated with Sjogren's is not excluded.

• Cigarette use of greater than 20 pack years or regular use within 6 months

• Allergy or intolerance to Pulmozyme.

• Acute respiratory infection or other acute respiratory illness during the prior month.

• LCQ greater than 17 and VAS less than 3 cm at baseline (Visit 1).

• Pregnancy or breast feeding.